Clinical trial DANUBE
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer
| Cancers | |
|---|---|
| Organ | Bladder |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2015-001633-24 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02516241 |
| Inclusion criteria | No prior exposure to immune-mediated therapy |
| Last update |